<DOC>
	<DOCNO>NCT00331513</DOCNO>
	<brief_summary>This randomized phase I trial study side effect best dose vorinostat give together idarubicin treat patient relapsed refractory leukemia myelodysplastic syndrome . Drugs use chemotherapy , vorinostat idarubicin , work different way stop growth cancer cell , either kill cell stop dividing . Vorinostat may also stop growth cancer cell block enzymes need cell growth . Giving vorinostat together idarubicin may kill cancer cell .</brief_summary>
	<brief_title>Vorinostat Idarubicin Treating Patients With Relapsed Refractory Leukemia Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose-limiting toxicity vorinostat ( SAHA ) combination standard-dose idarubicin patient relapse refractory acute myeloid leukemia , acute lymphocytic leukemia , myelodysplastic syndrome , acute promyelocytic leukemia , chronic myelogenous leukemia blastic phase . II . Describe clinical activity regimen patient . III . Determine vivo molecular effect regimen , include effect DNA topoisomerase IIα mRNA expression induction γH2AX , histone H3 H4 acetylation , well change gene expression profile . IV . Determine pharmacokinetic characteristic regimen patient . OUTLINE : This randomize , dose-escalation study vorinostat ( SAHA ) . Patients randomize 1 2 treatment arm . ARM I : Patients receive oral SAHA three time daily day 1-14 idarubicin IV 15 minute daily day 1-3 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . * ARM II : Patients receive oral SAHA three time daily idarubicin IV 15 minute daily day 1-3 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . * Note : *Patients complete 6 course therapy reach maximum cumulative dose idarubicin equivalent anthracycline achieve clinical benefit may continue treatment SAHA alone 3 time daily day 1-14 course , absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos SAHA maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . An additional 10 patient treated MTD . Patients undergo blood collection bone marrow biopsy periodically study pharmacologic , biomarker , genetic study . After completion study treatment , patient follow 4 week periodically thereafter .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patients must histologically cytologically confirm relapsed/refractory acute myelogenous leukemia , acute lymphocytic leukemia , myelodysplastic syndrome blastic phase chronic myelogenous leukemia . Patients receive cumulative dos ( equivalent anthracycline ) 290 mg/m^2 idarubicin exclude study . No limitation term number prior therapy type therapy apply study . ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Total bilirubin ≤ 2 mg/dL AST ALT ≤ 2.5 time upper limit normal Creatinine ≤ 2 mg/dL LVEF ≥ 50 % Not nursing pregnant Negative pregnancy test Fertile patient must use effective contraception At least 2 week since prior chemotherapy recover , unless evidence rapidly progressive disease , least 24 hour since prior hydroxyurea rapidly proliferate disease At least 2 week since prior imatinib mesylate At least 2 week since prior histone deacetylase inhibitor , include valproic acid Maximum cumulative dose prior idarubicin equivalent anthracycline drug ≤ 290 mg/m2 No concurrent epoetin alfa hematopoietic colonystimulating factor first course study therapy No concurrent prophylactic hematopoietic colonystimulating factor Myelodysplastic syndrome require treatment , previously treat either azacytidine decitabine , unless contraindicate ; blastic phase chronic myelogenous leukemia ; fail prior imatinib mesylatebased therapy Patients MDS receive therapy either 5azacytidine 5aza2'deoxycytidine , unless patient contraindication therapy , require therapy . Ability understand willingness sign write informed consent document . Patients clinical evidence CNS disease exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . No unstable angina pectoris Considered ineligible refuse potentially curative therapy , include allogeneic stem cell transplantation , without standard induction therapy No history allergic reaction attribute compound similar chemical biological composition vorinostat ( SAHA ) agent use study No ongoing active infection No symptomatic congestive heart failure No cardiac arrhythmia No uncontrolled illness No psychiatric illness social situation would preclude study compliance No concurrent investigational agent No concurrent anticancer agent therapies No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>